Please visit answersincme.com/WWC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC) in the real-world setting. Upon completion of this activity, participants should be better able to: Outline the clinical relevance of real-world evidence in the treatment of HR+/HER2- aBC; Review the latest real-world evidence informing the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- aBC; and Identify patient-centered strategies to integrate real-world evidence into optimized care plans for patients with HR+/HER2- aBC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related